A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer

被引：0
|
作者：
Hurvitz, S. A. [1 ]
Galsky, M. D. [2 ]
Shahidi, J. [3 ]
Zhang, G. [4 ]
Raza, S. [3 ]
Necchi, A. [5 ]
机构：
[1] UCLA Med Ctr, Dept Med, Los Angeles, CA USA
[2] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[3] Daiichi Sankyo Inc, Clin Dev, Basking Ridge, NJ USA
[4] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA
[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
    Xu, Zhuyu
    Guo, Dandan
    Jiang, Zhongliang
    Tong, Rongsheng
    Jiang, Peidu
    Bai, Lan
    Chen, Lu
    Zhu, Yuxuan
    Guo, Chun
    Shi, Jianyou
    Yu, Dongke
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 183
  • [32] Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or - Mutated Advanced Non-Small-Cell Lung Cancer
    Tsurutani, J.
    Park, H.
    Doi, T.
    Modi, S.
    Takahashi, S.
    Nakagawa, K.
    Krop, I.
    Waqar, S.
    Yoh, K.
    Li, B.
    Taira, S.
    Jikoh, T.
    Singh, J.
    Sugihara, M.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S324 - S324
  • [33] Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Li, Wenhua
    Chen, Yang
    Meng, Yanchun
    Liu, Chang
    Jin, Wenyue
    Wu, Junyan
    Wang, Ying
    Hao, Yanrong
    Yi, Shuli
    Qing, Yan
    Ge, Junyou
    Hu, Xichun
    NPJ BREAST CANCER, 2023, 9 (01)
  • [34] A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Modi, Shanu
    Ohtani, Shoichiro
    Lee, Caleb
    Wang, Yibin
    Saxena, Kapil
    Cameron, David A.
    CANCER RESEARCH, 2020, 80 (04)
  • [35] Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC)
    Hingorani, Pooja
    Zhang, Wendong
    Kurmasheva, Raushan
    Zhang, Zhongting
    Wang, Yifei
    Xu, Zhaohui
    Roth, Michael
    Gill, Jonathan
    Harrison, Douglas
    Erickson, Stephen
    Kolb, Edward A.
    Smith, Malcolm
    Houghton, Peter
    Gorlick, Richard
    CANCER RESEARCH, 2020, 80 (16)
  • [36] Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors
    Doi, Toshihiko
    Iwata, Hiroji
    Tsurutani, Junji
    Takahashi, Shunji
    Park, Haeseong
    Redfern, Charles H.
    Shitara, Kohei
    Shimizu, Chikako
    Taniguchi, Hiroya
    Iwasa, Tsutomu
    Taira, Shinichiro
    Lockhart, Albert C.
    Fisher, Jennifer M.
    Jikoh, Takahiro
    Fujisaki, Yoshihiko
    Lee, Caleb C.
    Yver, Antoine
    Tamura, Kenji
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression
    Mauricio, Dennis
    Bellone, Stefania
    Manavella, Diego
    Harold, Justin
    Buza, Natalia
    Altwerger, Gary
    Menderes, Gulden
    Ratner, Elena
    Huang, Gloria
    Clark, Mitchell
    Andikyan, Vaagn
    Azodi, Masoud
    Schwartz, Peter
    Santin, Alessandro
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S31 - S32
  • [38] Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
    Mauricio, Dennis
    Bellone, Stefania
    Mutlu, Levent
    McNamara, Blair
    Manavella, Diego D.
    Demirkiran, Cem
    Verzosa, Miguel Skyler Z.
    Buza, Natalia
    Hui, Pei
    Hartwich, Tobias Max Philipp
    Harold, Justin
    Yang-Hartwich, Yang
    Zipponi, Margherita
    Altwerger, Gary
    Ratner, Elena
    Huang, Gloria S.
    Clark, Mitchell
    Andikyan, Vaagn
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2023, 170 : 38 - 45
  • [39] Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs TDM1 for HER2-positive breast cancer
    Verma, S.
    Shahidi, J.
    Lee, C.
    Wang, K.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] [Fam-] Trastuzumab Deruxtecan (T-DXd; DS-8201a) in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: A Phase 2, Multicenter, Open-Label Study (DESTINY-Breast01)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 7 - 9
12345